001028207 001__ 1028207
001028207 005__ 20250203124529.0
001028207 0247_ $$2doi$$a10.1007/s00259-024-06783-x
001028207 0247_ $$2ISSN$$a1619-7070
001028207 0247_ $$2ISSN$$a1619-7089
001028207 0247_ $$2datacite_doi$$a10.34734/FZJ-2024-04402
001028207 0247_ $$2pmid$$a38898354
001028207 0247_ $$2WOS$$aWOS:001250257200001
001028207 037__ $$aFZJ-2024-04402
001028207 082__ $$a610
001028207 1001_ $$00000-0003-0953-7624$$aAlbert, Nathalie L.$$b0$$eCorresponding author
001028207 245__ $$aJoint EANM/EANO/RANO/SNMMI practice guideline/procedure standards for diagnostics and therapy (theranostics) of meningiomas using radiolabeled somatostatin receptor ligands: version 1.0
001028207 260__ $$aHeidelberg [u.a.]$$bSpringer-Verl.$$c2024
001028207 3367_ $$2DRIVER$$aarticle
001028207 3367_ $$2DataCite$$aOutput Types/Journal article
001028207 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1736944173_1723
001028207 3367_ $$2BibTeX$$aARTICLE
001028207 3367_ $$2ORCID$$aJOURNAL_ARTICLE
001028207 3367_ $$00$$2EndNote$$aJournal Article
001028207 520__ $$aAbstractPurposeTo provide practice guideline/procedure standards for diagnostics and therapy (theranostics) of meningiomas using radiolabeled somatostatin receptor (SSTR) ligands.MethodsThis joint practice guideline/procedure standard was collaboratively developed by the European Association of Nuclear Medicine (EANM), the Society of Nuclear Medicine and Molecular Imaging (SNMMI), the European Association of Neurooncology (EANO), and the PET task force of the Response Assessment in Neurooncology Working Group (PET/RANO).ResultsPositron emission tomography (PET) using somatostatin receptor (SSTR) ligands can detect meningioma tissue with high sensitivity and specificity and may provide clinically relevant information beyond that obtained from structural magnetic resonance imaging (MRI) or computed tomography (CT) imaging alone. SSTR-directed PET imaging can be particularly useful for differential diagnosis, delineation of meningioma extent, detection of osseous involvement, and the differentiation between posttherapeutic scar tissue and tumour recurrence. Moreover, SSTR-peptide receptor radionuclide therapy (PRRT) is an emerging investigational treatment approach for meningioma.ConclusionThese practice guidelines will define procedure standards for the application of PET imaging in patients with meningiomas and related SSTR-targeted PRRTs in routine practice and clinical trials and will help to harmonize data acquisition and interpretation across centers, facilitate comparability of studies, and to collect larger databases. The current document provides additional information to the evidence-based recommendations from the PET/RANO Working Group regarding the utilization of PET imaging in meningiomas Galldiks (Neuro Oncol. 2017;19(12):1576–87). The information provided should be considered in the context of local conditions and regulations.
001028207 536__ $$0G:(DE-HGF)POF4-5252$$a5252 - Brain Dysfunction and Plasticity (POF4-525)$$cPOF4-525$$fPOF IV$$x0
001028207 588__ $$aDataset connected to CrossRef, Journals: juser.fz-juelich.de
001028207 7001_ $$00000-0003-3541-2315$$aPreusser, Matthias$$b1
001028207 7001_ $$00000-0003-1118-926X$$aTraub-Weidinger, Tatjana$$b2
001028207 7001_ $$00000-0002-8005-2833$$aTolboom, Nelleke$$b3
001028207 7001_ $$0P:(DE-HGF)0$$aLaw, Ian$$b4
001028207 7001_ $$00000-0003-3311-0129$$aPalmer, Joshua D.$$b5
001028207 7001_ $$0P:(DE-HGF)0$$aGuedj, Eric$$b6
001028207 7001_ $$00000-0001-8258-3681$$aFurtner, Julia$$b7
001028207 7001_ $$0P:(DE-HGF)0$$aFraioli, Francesco$$b8
001028207 7001_ $$0P:(DE-HGF)0$$aHuang, Raymond Y.$$b9
001028207 7001_ $$0P:(DE-HGF)0$$aJohnson, Derek R.$$b10
001028207 7001_ $$00000-0002-6080-1577$$aDeroose, Christophe M.$$b11
001028207 7001_ $$00000-0002-9662-7259$$aHerrmann, Ken$$b12
001028207 7001_ $$0P:(DE-HGF)0$$aVogelbaum, Michael$$b13
001028207 7001_ $$0P:(DE-HGF)0$$aChang, Susan$$b14
001028207 7001_ $$0P:(DE-HGF)0$$aTonn, Joerg-Christian$$b15
001028207 7001_ $$0P:(DE-HGF)0$$aWeller, Michael$$b16
001028207 7001_ $$0P:(DE-HGF)0$$aWen, Patrick Y.$$b17
001028207 7001_ $$0P:(DE-HGF)0$$avan den Bent, Martin J.$$b18
001028207 7001_ $$0P:(DE-Juel1)171957$$aVerger, Antoine$$b19
001028207 7001_ $$0P:(DE-HGF)0$$aIvanidze, Jana$$b20
001028207 7001_ $$0P:(DE-Juel1)143792$$aGalldiks, Norbert$$b21$$ufzj
001028207 773__ $$0PERI:(DE-600)2098375-X$$a10.1007/s00259-024-06783-x$$gVol. 51, no. 12, p. 3662 - 3679$$n12$$p3662 - 3679$$tEuropean journal of nuclear medicine and molecular imaging$$v51$$x1619-7070$$y2024
001028207 8564_ $$uhttps://juser.fz-juelich.de/record/1028207/files/PDF.pdf$$yOpenAccess
001028207 8564_ $$uhttps://juser.fz-juelich.de/record/1028207/files/PDF.gif?subformat=icon$$xicon$$yOpenAccess
001028207 8564_ $$uhttps://juser.fz-juelich.de/record/1028207/files/PDF.jpg?subformat=icon-1440$$xicon-1440$$yOpenAccess
001028207 8564_ $$uhttps://juser.fz-juelich.de/record/1028207/files/PDF.jpg?subformat=icon-180$$xicon-180$$yOpenAccess
001028207 8564_ $$uhttps://juser.fz-juelich.de/record/1028207/files/PDF.jpg?subformat=icon-640$$xicon-640$$yOpenAccess
001028207 909CO $$ooai:juser.fz-juelich.de:1028207$$pdnbdelivery$$pdriver$$pVDB$$popen_access$$popenaire
001028207 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)143792$$aForschungszentrum Jülich$$b21$$kFZJ
001028207 9131_ $$0G:(DE-HGF)POF4-525$$1G:(DE-HGF)POF4-520$$2G:(DE-HGF)POF4-500$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$9G:(DE-HGF)POF4-5252$$aDE-HGF$$bKey Technologies$$lNatural, Artificial and Cognitive Information Processing$$vDecoding Brain Organization and Dysfunction$$x0
001028207 9141_ $$y2024
001028207 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2024-12-05
001028207 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2024-12-05
001028207 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences$$d2024-12-05
001028207 915__ $$0LIC:(DE-HGF)CCBY4$$2HGFVOC$$aCreative Commons Attribution CC BY 4.0
001028207 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2024-12-05
001028207 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bEUR J NUCL MED MOL I : 2022$$d2024-12-05
001028207 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2024-12-05
001028207 915__ $$0StatID:(DE-HGF)3002$$2StatID$$aDEAL Springer$$d2024-12-05$$wger
001028207 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2024-12-05
001028207 915__ $$0StatID:(DE-HGF)0510$$2StatID$$aOpenAccess
001028207 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2024-12-05
001028207 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bEUR J NUCL MED MOL I : 2022$$d2024-12-05
001028207 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2024-12-05
001028207 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2024-12-05
001028207 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2024-12-05
001028207 920__ $$lyes
001028207 9201_ $$0I:(DE-Juel1)INM-3-20090406$$kINM-3$$lKognitive Neurowissenschaften$$x0
001028207 980__ $$ajournal
001028207 980__ $$aVDB
001028207 980__ $$aUNRESTRICTED
001028207 980__ $$aI:(DE-Juel1)INM-3-20090406
001028207 9801_ $$aFullTexts